MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ymthe.2026.05.027

Медицинская библиотека · Molecular therapy : the journal of the American Society of Gene Therapy · 2026

Depletion of CD8+ CART cells leads to superior anti-tumor efficacy of pure CD4+ CART cells against acute leukemias.

Chen Qian, Sedloev David, Yao Hao, Mao Lianghao, Depke Dominic, Wang Lei, Scheller Marina, He Bailin, Liu Yi, Unglaub Julia M, Schmitt Anita, Jayavelu Ashok Kumar, Müller-Tidow Carsten, Schmitt Michael, Sauer Tim

СтатьяПеревод пока не подготовлен

Аннотация

Chimeric antigen receptor T (CART) cell therapy has demonstrated clinical efficacy in hematologic malignancies; however, primary or secondary treatment failure remains a major obstacle to durable responses. Defining the optimal cellular composition of CART products therefore represents a critical unmet need. Here, we show that CARTs targeting acute leukemias achieve maximal efficacy when composed exclusively of CD4+ T cells. Pure CD4+ CARTs exhibit superior anti-tumor activity and proliferation compared with CD8+-containing CART products. To elucidate the molecular basis of this functional divergence, we applied a combinatorial exploratory approach integrating bulk RNA sequencing and quantitative proteomics. Transcriptomic analyses revealed that pure CD4+ CARTs adopt a highly proliferative state characterized by a cytotoxic effector-like polarization. On the protein level, we are demonstrating coordinated loss of cell-cycle machinery and induction of apoptotic pathways in CD4+ CART cells co-cultured together with CD8+ CART cells, while pure CD4+ CART cultures maintained a proliferative, cytotoxic phenotype. Using mechanistically discriminative co-culture systems, we demonstrate that CD8+ CART-mediated impairment of CD4+ CART functionality is primarily driven by competitive access to shared antigen. Collectively, these findings identify antigen competition between CART subsets as a previously unrecognized mechanism limiting CD4+ CART efficacy and provide a framework for optimizing CART product composition to enhance therapeutic persistence and durability.

Для цитирования: Chen Qian, Sedloev David, Yao Hao, Mao Lianghao, Depke Dominic, Wang Lei, Scheller Marina, He Bailin, Liu Yi, Unglaub Julia M, Schmitt Anita, Jayavelu Ashok Kumar, Müller-Tidow Carsten, Schmitt Michael, Sauer Tim. Depletion of CD8+ CART cells leads to superior anti-tumor efficacy of pure CD4+ CART cells against acute leukemias.. Molecular therapy : the journal of the American Society of Gene Therapy. 2026. DOI: 10.1016/j.ymthe.2026.05.027.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.